Houston, Texas 77030

  • Kidney Neoplasms


The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).


Inclusion Criteria: - ≥ 18 years old - Histologically confirmed renal cell carcinoma with clinically or pathologically confirmed progression - Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior treatments - Measurable disease - Hemoglobin ≥ 9 mg/dL - ECOG performance status of 0, 1, or 2 - Willing and able to provide written informed consent Exclusion Criteria: - Inadequate bone marrow, renal and liver function by laboratory criteria - Absolute neutrophil count < 1500/µL; - Platelet count < 100,000/µL; - AST or ALT > 2 x upper limit of normal (ULN); - Alkaline phosphatase > 5 x ULN; - Total bilirubin > 2 x ULN; - Creatinine > 2.0 mg/dL. - Evidence of central nervous system metastases within past year - Uncontrolled hypertension - Known history of porphyria, G6PD deficiency or HIV



Primary Contact:

Principal Investigator
Robert J Amato, D.O.
Methodist Hospital Genitourinary Oncology

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.